Expert Financial Analysis and Reporting

Reason for Report At the request of some subscribers to my website, I have been asked to take a look at the bull and bear case on Spectrum Pharmaceuticals and try to fairly represent the positives and negatives of each point of view. There is strong bearish sentiment as short interest accounts for 52% of […]

Investment Opinion I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb (BMY). The acquisition of Amylin (AMLN) has some tactical appeal as it strengthens BMY’s position in the diabetes market, is only modestly dilutive in the near term and could […]

Investment Thesis The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that  in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP […]

Investment Summary and Thesis In my report of May 31, 2012, I stated that management guidance for Ofirmev sales of $10.0 to $10.5 million for 2Q, 2012 seemed low and I was using a higher estimate of $10.5 million to $11.1 million. Cadence just released market research data on the number of Ofirmev vials shipped […]

Report Overview The core technology of InSite Vision is its DuraSite delivery system that delivers drugs more effectively to the eye. The continual blinking of the eye can quickly wash out topical formulations and in order to retain effective drug levels in eye tissue, most drugs have to be given four to eight times per […]

Purpose of Report Discovery Laboratories (DSCO) held a quarterly conference call on May 3 to update investors on the pending launch of Surfaxin and Afectair. This followed an important press release the day earlier that discussed a paper presented at the 2012 Pediatric Academies Society Annual Conference in Boston. This report highlights the key points […]

Cadence Pharmaceuticals: The Ofirmev Launch is Gaining Traction (CADX, $xx) Investment Thesis I believe that Ofirmev, an intravenous formulation of acetaminophen, has significant potential as an alternative to intravenous opioids and non-steroidal anti-inflammatories analgesics that are used broadly in the hospital. This potential is well illustrated by its launch in the UK where it is […]

Introduction Trius Therapeutics is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as […]

Conclusion I believe that the settlement on the EpiPen litigation is a positive for Antares. It pushes the launch date for the generic epinephrine injector from 2013 to 2015. However, during this time, EpiPen sales are expected to grow rapidly increasing from $600 million in 2012 to $1.3 billion in 2015. Based on calculations shown […]

Dendritic Cell-Based Cancer Vaccines Could Be a Major Advance In October of 2011, Dr. Ralph Steinman was post-humously awarded one-half of the Nobel Prize in Physiology or Medicine for his discoveries of the dendritic cell and its role in adaptive immunity. His discoveries have made possible the development of therapeutic cancer vaccines that are produced […]